Delirium. Delirium due to known physiological condition
Conditions
Interventions
Intervention 1: Intervention group: Oral agomelatine is prescribed at a dose of 25 mg every night at 6 p.m. and is manufactured by Tadbir Kalay Jam Company (Tagajeh). Intervention 2: Control group: Co
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age: Individuals over 18 years of age admitted to the intensive care unit Informed consent Oral route: Patients are able to receive medication orally or via an orogastric/nasogastric tube.
Exclusion criteria
Exclusion criteria: Severe hepatic dysfunction: or elevation of transaminases to more than three times the upper limit of normal Contraindications to agomelatine: Known hypersensitivity or adverse reactions to agomelatine. Severe cognitive impairment: Patients with advanced dementia or other severe cognitive impairment that make meaningful assessment of delirium impossible. Drug interactions: Taking medications that may severely interact with agomelatine (such as cytochrome P450 1A2 inhibitors such as fluvoxamine) Pregnancy or lactation: Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of delirium. Timepoint: To investigate the incidence of delirium in patients admitted to the intensive care unit, they were assessed upon entry into the study and then daily thereafter. Method of measurement: CAM ICU, Richmond sedation scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identifying a treatment method to reduce the incidence of delirium in patients admitted to the intensive care unit. Timepoint: It will be determined at the end of the study. Method of measurement: CAM ICU , richmond sedation scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Farrokhian
Shahid Beheshti University of Medical Sciences
Outcome results
None listed